Braveheart Bio Q2 FY26 net loss widens to $15 million; R&D expenses rise to $11.1 million
BRVE•Cash position and runway
Cash and cash equivalents were $122.8 million at June 30; $527.3 million as adjusted for the IPO, expected to fund operations into 2029.
Q2 loss widens as R&D and G&A expenses rise
Braveheart Bio posted a Q2 net loss of $15 million, versus a $0.4 million loss a year earlier.
Net loss attributable to common stockholders widened to $18.6 million, from $0.4 million; loss per share deepened to $2.51 from $0.14.
R&D expenses climbed to $11.1 million from no R&D expense, due to BHB-1893 advancement and Phase 3 preparation.
G&A expenses rose to $4.8 million from less than $0.1 million, on higher headcount and public-company readiness costs.
